The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a parallel group, double blind, vehicle‐controlled study in which roflumilast (ARQ‐151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.
Epistemonikos ID: 29378ed8980bc9b63051ffd87f4ccfcb4bf99b65
First added on: May 21, 2024